Lilly's Moat Still Intact After Halting Heart Drug Study
Given the stock's major pullback on the discontinuation announcement, we now see Lilly as fairly valued.
We plan to reduce our
Lilly ended the drug's pivotal Phase III study based on a data-monitoring committee's suggestion that the drug would not achieve a cardiovascular benefit. Despite the large potential for the drug, we had only modeled in $1 billion in peak sales potential (in line with consensus expectations) because of the high uncertainty of approval, as several similar drugs failed in late-stage development.
Nevertheless, we still view Lilly's moat as wide, buoyed by a strong late-stage pipeline and manageable patent losses over the next five years. Given the stock's major pullback on the discontinuation announcement, we now see Lilly as fairly valued.
Beyond the implications for Eli Lilly, the evacetrapib failure reduces odds of success for
Morningstar Premium Members gain exclusive access to our full Eli Lilly Report, including fair value estimates, consider buying/selling prices, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
United States